$Savara (SVRA.US)$ NEWS Savara Presented New Data on Autoimm...
NEWS
Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
Savara (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented significant data at the American Thoracic Society (ATS) 2024 International Conference. The event, taking place from May 17-22, 2024, in San Diego, CA, featured two important posters.
Poster Board 701, sponsored by Savara, detailed a cohort study revealing that pulmonary alveolar proteinosis (PAP) patients face a substantial healthcare burden. This includes a 4-fold increase in hospital admissions and costs compared to non-PAP controls.
Poster Board 702, presented by Trillium Health , showcased a novel laboratory test for diagnosing autoimmune pulmonary alveolar proteinosis (aPAP) with 100% clinical accuracy. This test detects GM-CSF antibodies in human serum, offering a precise and sensitive diagnostic tool.
Poster Board 701, sponsored by Savara, detailed a cohort study revealing that pulmonary alveolar proteinosis (PAP) patients face a substantial healthcare burden. This includes a 4-fold increase in hospital admissions and costs compared to non-PAP controls.
Poster Board 702, presented by Trillium Health , showcased a novel laboratory test for diagnosing autoimmune pulmonary alveolar proteinosis (aPAP) with 100% clinical accuracy. This test detects GM-CSF antibodies in human serum, offering a precise and sensitive diagnostic tool.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
840Followers
62Following
5574Visitors
Follow